Q32 Bio Inc. (QTTB): Cash & Equivalents
$48.30M
As of 2025-12-31
$106.27M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $48.30M | -38.1% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $77.97M | +204.3% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $25.62M | n/c | 2025-03-11, Balance as of period end |
| 2022-12-31 | $33.99M | -68.6% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $108.38M | -50.2% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $217.43M | +304.3% | 2022-03-23, Balance as of period end |
| 2019-12-31 | $53.77M | +40.7% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $38.22M | -25.9% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $51.58M | n/a | 2019-03-12, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $48.30M | -38.1% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $89.13M | +16.9% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $3.62M | +115.6% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $15.12M | -65.8% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $737.06M | +88.0% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $26.31M | -15.0% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $34.33M | -48.5% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $37.73M | -18.1% |
| Journey Medical Corp (DERM) | 2025-12-31 | $24.09M | +18.6% |
Compare QTTB, AGIO, INBP, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗